Reshaping the future of treating and preventing cancer and infectious diseases by activating antigen-specific immune responses
Inovio is bringing IMMUNO-INGENUITY™ to life and is reshaping the future of treating and preventing cancer and infectious diseases.
Inovio's technology platform is capable of activating antigen-specific immune responses. With demonstrated efficacy in a Phase 2b trial, robust and targeted immune responses, a favorable safety profile, and a robust pipeline of product candidates across multiple disease states, the evidence to date is clear—Inovio is realizing the true promise of immunotherapy.
Visit website: https://www.inovio.com/
People at Inovio
Pharmaceutical companies developing vaccine for coronavirus in record time (video)
BBC - 31-Jan-2020
Inovio's Dr Kate Broderick explains how - starting with the DNA sequenceRead more...